This report aims to provide a comprehensive presentation of the global market for Neuromyelitis Optica Spectrum Disorder, with and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuromyelitis Optica Spectrum Disorder.
The Neuromyelitis Optica Spectrum Disorder market size considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Neuromyelitis Optica Spectrum Disorder market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neuromyelitis Optica Spectrum Disorder manufacturers, new entrants, and industry chain related companies in this market with information for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
The global Neuromyelitis Optica Spectrum Disorder market size in 2022 is 410.50 million US dollars, and it is expected to be 623.38 million US dollars by 2029, with a compound annual growth rate of 6.15% expected in 2023-2029.
MARKET COMPETITIVE LANDSCAPE:
The main players in the Neuromyelitis Optica Spectrum Disorder market include F. Hoffmann-La RocheLtd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), and GlaxoSmithKline plc (U.K.). The share of the top 3 players in the Neuromyelitis Optica Spectrum Disorder market is XX%.
REGION SHARE:
The report covers the market size information of North America, Europe, Asia Pacific, Latin America, Middle East and Africa, in which North America accounted for XX%, Europe accounted for XX% of Neuromyelitis Optica Spectrum Disorder market, and Asia Pacific accounted for XX%.
SEGMENT OVERVIEW:
The report segments the market by Type and Application. C5 Protein Inhibitor accounted for XX% of Neuromyelitis Optica Spectrum Disorder market in 2022. Monoclonal Antibodies share of XX%.
Hospital Pharmacy accounted for XX% of the Neuromyelitis Optica Spectrum Disorder market in 2022. Retail Pharmacy accounts for XX%.
Chapter Outline
Chapter 1: Introduces the product overview, market scope, product classification, and application division, and then includes research purposes, report timeline, and economic analysis of global regions.
Chapter 2: Analyzes the main companies in the Neuromyelitis Optica Spectrum Disorder industry, including their main businesses, products/services, revenue, gross and gross margin.
Chapters 3-5: Segmented the global Neuromyelitis Optica Spectrum Disorder market by type, application and region. Analyze the revenue and sales of market segments from different perspectives.
Chapters 6-11: Provide North America, EMEA, China, Asia-Pacific and Latin America Neuromyelitis Optica Spectrum Disorder market type, application, country and player market segmentation revenue data.
Chapter 12: Introduces the market dynamics, the trends factors and drivers factors of the market, and the challenges and restraints faced by manufacturers in the industry, and includes industry mergers & acquisitions and industry new entrants and expansion plans.
Chapter 13: The main points and conclusions of the report.
Highlights-Regions
North America
United States
Canada
China
Asia Pacific (Excluding China)
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Nordic
Latin America
Brazil
Argentina
Mexico
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Player list
F. Hoffmann-La RocheLtd. (Switzerland)
Mylan N.V. (U.S.)
Teva Pharmaceutical Industries Ltd. (Israel)
Sanofi (France), Pfizer Inc. (U.S.)
GlaxoSmithKline plc (U.K.)
Novartis AG (Switzerland)
Zydus Cadila (India)
Boehringer Ingelheim International GmbH. (Germany)
Apotex Inc. (Canada)
AstraZeneca (U.K.)
Horizon Therapeutics PLC (Ireland)
Johnson & Johnson Private Limited (U.S.)
Bayer
Sun Pharmaceutical Industries Ltd. (India)
LEO Pharma A/S (Denmark)
Bausch Health Companies Inc. (Canada)
Allergan (Ireland)
Eli Lilly and Company (U.S.)
Aurobindo Pharma (India)
Lupin (India)
TG Therapeutics
Opexa Therapeutics
Mitsubishi Tanabe Pharma
Types list
C5 Protein Inhibitor
Monoclonal Antibodies
Plasma Exchange Therapy
Corticosteroids
Immunoglobulin Therapy
Medication
Others
Application list
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
List of Tables and Figures
Figure Neuromyelitis Optica Spectrum Disorder Picture
Table Product Definition of Neuromyelitis Optica Spectrum Disorder
Table Global Neuromyelitis Optica Spectrum Disorder Market Size by Type (2023 VS 2029)
Table Global Neuromyelitis Optica Spectrum Disorder Market Size by Application (2023 VS 2029)
Table F. Hoffmann-La RocheLtd. (Switzerland) Profile
Table Product Overview
Table F. Hoffmann-La RocheLtd. (Switzerland) Neuromyelitis Optica Spectrum Disorder Revenue, Gross and Gross Margin (2018-2023)
Figure F. Hoffmann-La RocheLtd. (Switzerland) Revenue and Growth Rate
Figure F. Hoffmann-La RocheLtd. (Switzerland) Revenue Market Share 2017-2022
Table Business Overview
Table Mylan N.V. (U.S.) Profile
Table Product Overview
Table Mylan N.V. (U.S.) Neuromyelitis Optica Spectrum Disorder Revenue, Gross and Gross Margin (2018-2023)
Figure Mylan N.V. (U.S.) Revenue and Growth Rate
Figure Mylan N.V. (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Teva Pharmaceutical Industries Ltd. (Israel) Profile
Table Product Overview
Table Teva Pharmaceutical Industries Ltd. (Israel) Neuromyelitis Optica Spectrum Disorder Revenue, Gross and Gross Margin (2018-2023)
Figure Teva Pharmaceutical Industries Ltd. (Israel) Revenue and Growth Rate
Figure Teva Pharmaceutical Industries Ltd. (Israel) Revenue Market Share 2017-2022
Table Business Overview
Table Sanofi (France), Pfizer Inc. (U.S.) Profile
Table Product Overview
Table Sanofi (France), Pfizer Inc. (U.S.) Neuromyelitis Optica Spectrum Disorder Revenue, Gross and Gross Margin (2018-2023)
Figure Sanofi (France), Pfizer Inc. (U.S.) Revenue and Growth Rate
Figure Sanofi (France), Pfizer Inc. (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table GlaxoSmithKline plc (U.K.) Profile
Table Product Overview
Table GlaxoSmithKline plc (U.K.) Neuromyelitis Optica Spectrum Disorder Revenue, Gross and Gross Margin (2018-2023)
Figure GlaxoSmithKline plc (U.K.) Revenue and Growth Rate
Figure GlaxoSmithKline plc (U.K.) Revenue Market Share 2017-2022
Table Business Overview
Table Novartis AG (Switzerland) Profile
Table Product Overview
Table Novartis AG (Switzerland) Neuromyelitis Optica Spectrum Disorder Revenue, Gross and Gross Margin (2018-2023)
Figure Novartis AG (Switzerland) Revenue and Growth Rate
Figure Novartis AG (Switzerland) Revenue Market Share 2017-2022
Table Business Overview
Table Zydus Cadila (India) Profile
Table Product Overview
Table Zydus Cadila (India) Neuromyelitis Optica Spectrum Disorder Revenue, Gross and Gross Margin (2018-2023)
Figure Zydus Cadila (India) Revenue and Growth Rate
Figure Zydus Cadila (India) Revenue Market Share 2017-2022
Table Business Overview
Table Boehringer Ingelheim International GmbH. (Germany) Profile
Table Product Overview
Table Boehringer Ingelheim International GmbH. (Germany) Neuromyelitis Optica Spectrum Disorder Revenue, Gross and Gross Margin (2018-2023)
Figure Boehringer Ingelheim International GmbH. (Germany) Revenue and Growth Rate
Figure Boehringer Ingelheim International GmbH. (Germany) Revenue Market Share 2017-2022
Table Business Overview
Table Apotex Inc. (Canada) Profile
Table Product Overview
Table Apotex Inc. (Canada) Neuromyelitis Optica Spectrum Disorder Revenue, Gross and Gross Margin (2018-2023)
Figure Apotex Inc. (Canada) Revenue and Growth Rate
Figure Apotex Inc. (Canada) Revenue Market Share 2017-2022
Table Business Overview
Table AstraZeneca (U.K.) Profile
Table Product Overview
Table AstraZeneca (U.K.) Neuromyelitis Optica Spectrum Disorder Revenue, Gross and Gross Margin (2018-2023)
Figure AstraZeneca (U.K.) Revenue and Growth Rate
Figure AstraZeneca (U.K.) Revenue Market Share 2017-2022
Table Business Overview
Table Horizon Therapeutics PLC (Ireland) Profile
Table Product Overview
Table Horizon Therapeutics PLC (Ireland) Neuromyelitis Optica Spectrum Disorder Revenue, Gross and Gross Margin (2018-2023)
Figure Horizon Therapeutics PLC (Ireland) Revenue and Growth Rate
Figure Horizon Therapeutics PLC (Ireland) Revenue Market Share 2017-2022
Table Business Overview
Table Johnson & Johnson Private Limited (U.S.) Profile
Table Product Overview
Table Johnson & Johnson Private Limited (U.S.) Neuromyelitis Optica Spectrum Disorder Revenue, Gross and Gross Margin (2018-2023)
Figure Johnson & Johnson Private Limited (U.S.) Revenue and Growth Rate
Figure Johnson & Johnson Private Limited (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Bayer Profile
Table Product Overview
Table Bayer Neuromyelitis Optica Spectrum Disorder Revenue, Gross and Gross Margin (2018-2023)
Figure Bayer Revenue and Growth Rate
Figure Bayer Revenue Market Share 2017-2022
Table Business Overview
Table Sun Pharmaceutical Industries Ltd. (India) Profile
Table Product Overview
Table Sun Pharmaceutical Industries Ltd. (India) Neuromyelitis Optica Spectrum Disorder Revenue, Gross and Gross Margin (2018-2023)
Figure Sun Pharmaceutical Industries Ltd. (India) Revenue and Growth Rate
Figure Sun Pharmaceutical Industries Ltd. (India) Revenue Market Share 2017-2022
Table Business Overview
Table LEO Pharma A/S (Denmark) Profile
Table Product Overview
Table LEO Pharma A/S (Denmark) Neuromyelitis Optica Spectrum Disorder Revenue, Gross and Gross Margin (2018-2023)
Figure LEO Pharma A/S (Denmark) Revenue and Growth Rate
Figure LEO Pharma A/S (Denmark) Revenue Market Share 2017-2022
Table Business Overview
Table Bausch Health Companies Inc. (Canada) Profile
Table Product Overview
Table Bausch Health Companies Inc. (Canada) Neuromyelitis Optica Spectrum Disorder Revenue, Gross and Gross Margin (2018-2023)
Figure Bausch Health Companies Inc. (Canada) Revenue and Growth Rate
Figure Bausch Health Companies Inc. (Canada) Revenue Market Share 2017-2022
Table Business Overview
Table Allergan (Ireland) Profile
Table Product Overview
Table Allergan (Ireland) Neuromyelitis Optica Spectrum Disorder Revenue, Gross and Gross Margin (2018-2023)
Figure Allergan (Ireland) Revenue and Growth Rate
Figure Allergan (Ireland) Revenue Market Share 2017-2022
Table Business Overview
Table Eli Lilly and Company (U.S.) Profile
Table Product Overview
Table Eli Lilly and Company (U.S.) Neuromyelitis Optica Spectrum Disorder Revenue, Gross and Gross Margin (2018-2023)
Figure Eli Lilly and Company (U.S.) Revenue and Growth Rate
Figure Eli Lilly and Company (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Aurobindo Pharma (India) Profile
Table Product Overview
Table Aurobindo Pharma (India) Neuromyelitis Optica Spectrum Disorder Revenue, Gross and Gross Margin (2018-2023)
Figure Aurobindo Pharma (India) Revenue and Growth Rate
Figure Aurobindo Pharma (India) Revenue Market Share 2017-2022
Table Business Overview
Table Lupin (India) Profile
Table Product Overview
Table Lupin (India) Neuromyelitis Optica Spectrum Disorder Revenue, Gross and Gross Margin (2018-2023)
Figure Lupin (India) Revenue and Growth Rate
Figure Lupin (India) Revenue Market Share 2017-2022
Table Business Overview
Table TG Therapeutics Profile
Table Product Overview
Table TG Therapeutics Neuromyelitis Optica Spectrum Disorder Revenue, Gross and Gross Margin (2018-2023)
Figure TG Therapeutics Revenue and Growth Rate
Figure TG Therapeutics Revenue Market Share 2017-2022
Table Business Overview
Table Opexa Therapeutics Profile
Table Product Overview
Table Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder Revenue, Gross and Gross Margin (2018-2023)
Figure Opexa Therapeutics Revenue and Growth Rate
Figure Opexa Therapeutics Revenue Market Share 2017-2022
Table Business Overview
Table Mitsubishi Tanabe Pharma Profile
Table Product Overview
Table Mitsubishi Tanabe Pharma Neuromyelitis Optica Spectrum Disorder Revenue, Gross and Gross Margin (2018-2023)
Figure Mitsubishi Tanabe Pharma Revenue and Growth Rate
Figure Mitsubishi Tanabe Pharma Revenue Market Share 2017-2022
Table Business Overview
Table Global Neuromyelitis Optica Spectrum Disorder Revenue and Market Size by Type (2018-2023)
Table Global Neuromyelitis Optica Spectrum Disorder Revenue and Market Share by Type (2018-2023)
Table Global Neuromyelitis Optica Spectrum Disorder Revenue Market Size Forecast by Type (2023-2029)
Table Global Neuromyelitis Optica Spectrum Disorder Revenue Market Share Forecast by Type (2023-2029)
Table Global Neuromyelitis Optica Spectrum Disorder Revenue Market Size by Application (2018-2023)
Table Global Neuromyelitis Optica Spectrum Disorder Revenue Market Share by Application (2018-2023)
Table Global Neuromyelitis Optica Spectrum Disorder Revenue Market Size by Application (2023-2029)
Table Global Neuromyelitis Optica Spectrum Disorder Revenue Market Share by Application (2023-2029)
Figure Global Neuromyelitis Optica Spectrum Disorder Revenue Market Size & Forecast (2018-2029)
Table Neuromyelitis Optica Spectrum Disorder Market Size by Regions: 2018 VS 2023 VS 2029
Table Neuromyelitis Optica Spectrum Disorder Historic Revenue Market Size by Regions (2018-2023)
Table Neuromyelitis Optica Spectrum Disorder Historic Revenue Market Share by Regions (2018-2023)
Table Neuromyelitis Optica Spectrum Disorder Forecasted Revenue Market Size by Regions (2023-2029)
Table Neuromyelitis Optica Spectrum Disorder Forecasted Revenue Market Share by Regions (2023-2029)
Figure North America Neuromyelitis Optica Spectrum Disorder Market Size & Forecast (2018-2029)
Figure Europe Neuromyelitis Optica Spectrum Disorder Market Size & Forecast (2018-2029)
Figure China Neuromyelitis Optica Spectrum Disorder Market Size & Forecast (2018-2029)
Figure Asia-Pacific (Excluding China) Neuromyelitis Optica Spectrum Disorder Market Size & Forecast (2018-2029)
Figure Latin America Neuromyelitis Optica Spectrum Disorder Market Size & Forecast (2018-2029)
Figure Middle East & Africa Neuromyelitis Optica Spectrum Disorder Market Size & Forecast (2018-2029)
Table North America Neuromyelitis Optica Spectrum Disorder Revenue Share by Players 2022
Table North America Neuromyelitis Optica Spectrum Disorder Revenue by Types (2018-2023)
Table North America Neuromyelitis Optica Spectrum Disorder Revenue Market Share by Types (2018-2023)
Table North America Neuromyelitis Optica Spectrum Disorder Revenue by Applications (2018-2023)
Table North America Neuromyelitis Optica Spectrum Disorder Revenue Market Share by Applications (2018-2023)
Table North America Neuromyelitis Optica Spectrum Disorder Revenue by Countries (2018-2029)
Table North America Neuromyelitis Optica Spectrum Disorder Revenue Market Share by Countries (2018-2029)
Figure United States Neuromyelitis Optica Spectrum Disorder Revenue and Growth (2018-2029)
Figure Canada Neuromyelitis Optica Spectrum Disorder Revenue and Growth (2018-2029)
Table China Neuromyelitis Optica Spectrum Disorder Revenue Share by Players 2022
Table China Neuromyelitis Optica Spectrum Disorder Revenue by Types (2018-2023)
Table China Neuromyelitis Optica Spectrum Disorder Revenue Market Share by Types (2018-2023)
Table China Neuromyelitis Optica Spectrum Disorder Revenue by Applications (2018-2023)
Table China Neuromyelitis Optica Spectrum Disorder Revenue Market Share by Applications (2018-2023)
Figure China Neuromyelitis Optica Spectrum Disorder Revenue and Growth (2018-2029)
Table Asia Pacific Neuromyelitis Optica Spectrum Disorder Revenue Share by Players 2022
Table Asia Pacific Neuromyelitis Optica Spectrum Disorder Revenue by Types (2018-2023)
Table Asia Pacific Neuromyelitis Optica Spectrum Disorder Revenue Market Share by Types (2018-2023)
Table Asia Pacific Neuromyelitis Optica Spectrum Disorder Revenue by Applications (2018-2023)
Table Asia Pacific Neuromyelitis Optica Spectrum Disorder Revenue Market Share by Applications (2018-2023)
Table Asia-Pacific Neuromyelitis Optica Spectrum Disorder Revenue by Countries (2018-2029)
Table Asia-Pacific Neuromyelitis Optica Spectrum Disorder Revenue Market Share by Countries (2018-2029)
Figure Japan Neuromyelitis Optica Spectrum Disorder Revenue and Growth (2018-2029)
Figure Korea Neuromyelitis Optica Spectrum Disorder Revenue and Growth (2018-2029)
Figure Southeast Asia Neuromyelitis Optica Spectrum Disorder Revenue and Growth (2018-2029)
Figure India Neuromyelitis Optica Spectrum Disorder Revenue and Growth (2018-2029)
Figure Australia Neuromyelitis Optica Spectrum Disorder Revenue and Growth (2018-2029)
Table Europe Neuromyelitis Optica Spectrum Disorder Revenue Share by Players 2022
Table Europe Neuromyelitis Optica Spectrum Disorder Revenue by Types (2018-2023)
Table Europe Neuromyelitis Optica Spectrum Disorder Revenue Market Share by Types (2018-2023)
Table Europe Neuromyelitis Optica Spectrum Disorder Revenue by Applications (2018-2023)
Table Europe Neuromyelitis Optica Spectrum Disorder Revenue Market Share by Applications (2018-2023)
Table Europe Neuromyelitis Optica Spectrum Disorder Revenue by Countries (2018-2029)
Table Europe Neuromyelitis Optica Spectrum Disorder Revenue Market Share by Countries (2018-2029)
Figure Germany Neuromyelitis Optica Spectrum Disorder Revenue and Growth (2018-2029)
Figure France Neuromyelitis Optica Spectrum Disorder Revenue and Growth (2018-2029)
Figure UK Neuromyelitis Optica Spectrum Disorder Revenue and Growth (2018-2029)
Figure Italy Neuromyelitis Optica Spectrum Disorder Revenue and Growth (2018-2029)
Figure Russia Neuromyelitis Optica Spectrum Disorder Revenue and Growth (2018-2029)
Figure Nordic Neuromyelitis Optica Spectrum Disorder Revenue and Growth (2018-2029)
Table Latin America Neuromyelitis Optica Spectrum Disorder Revenue Share by Players 2022
Table Latin America Neuromyelitis Optica Spectrum Disorder Revenue by Types (2018-2023)
Table Latin America Neuromyelitis Optica Spectrum Disorder Revenue Market Share by Types (2018-2023)
Table Latin America Neuromyelitis Optica Spectrum Disorder Revenue by Applications (2018-2023)
Table Latin America Neuromyelitis Optica Spectrum Disorder Revenue Market Share by Applications (2018-2023)
Table Latin America Neuromyelitis Optica Spectrum Disorder Revenue by Countries (2018-2029)
Table Latin America Neuromyelitis Optica Spectrum Disorder Revenue Market Share by Countries (2018-2029)
Figure Brazil Neuromyelitis Optica Spectrum Disorder Revenue and Growth (2018-2029)
Figure Argentina Neuromyelitis Optica Spectrum Disorder Revenue and Growth (2018-2029)
Figure Mexico Neuromyelitis Optica Spectrum Disorder Revenue and Growth (2018-2029)
Table Latin America Neuromyelitis Optica Spectrum Disorder Revenue Share by Players 2022
Table Middle East & Africa Neuromyelitis Optica Spectrum Disorder Revenue by Types (2018-2023)
Table Middle East & Africa Neuromyelitis Optica Spectrum Disorder Revenue Market Share by Types (2018-2023)
Table Middle East & Africa Neuromyelitis Optica Spectrum Disorder Revenue by Applications (2018-2023)
Table Middle East & Africa Neuromyelitis Optica Spectrum Disorder Revenue Market Share by Applications (2018-2023)
Table Middle East & Africa Neuromyelitis Optica Spectrum Disorder Revenue by Countries (2018-2029)
Table Middle East & Africa Neuromyelitis Optica Spectrum Disorder Revenue Market Share by Countries (2018-2029)
Figure Egypt Neuromyelitis Optica Spectrum Disorder Revenue and Growth (2018-2029)
Figure South Africa Neuromyelitis Optica Spectrum Disorder Revenue and Growth (2018-2029)
Figure Israel Neuromyelitis Optica Spectrum Disorder Revenue and Growth (2018-2029)
Figure Turkey Neuromyelitis Optica Spectrum Disorder Revenue and Growth (2018-2029)
Figure GCC Countries Neuromyelitis Optica Spectrum Disorder Revenue and Growth (2018-2029)
Table Market Trends Analysis
Table Market Drivers Analysis
Table Market Challenges Analysis
Table Market Restraints Analysis
Table Market Mergers & Acquisitions
Table Market New Entrants and Expansion Plans
